Assessing the clinical utility of measuring Insulin-like Growth Factor Binding Proteins in tissues and sera of melanoma patients

Journal of Translational Medicine

Volumn 6, Issue , 2008, Pages

  Yu, Jessie Z ^a   Warycha, Melanie A ^a   Christos, Paul J ^b   Darvishian, Farbod ^a   Yee, Herman ^a   Kaminio, Hideko ^a   Berman, Russell S ^a   Shapiro, Richard L ^a   Buckley, Michael T ^a   Liebes, Leonard F ^a   Pavlick, Anna C ^a   Polsky, David ^a   Brooks, Peter C ^c   Osman, Iman ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MAINE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; TUMOR MARKER;

ADULT; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; METASTASIS POTENTIAL; PRIMARY TUMOR; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE DISTRIBUTION; BLOOD; METABOLISM; MIDDLE AGED; PATHOLOGY;

DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4; MALE; MELANOMA; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 58749084501     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-6-70     Document Type: Article

References (35)

1. Tao Y Pinzi V Bourhis J Deutsch E Mechanisms of disease: Signaling of the insulin-like growth factor 1 receptor pathway-therapeutic perspectives in cancer Nat Clin Pract Oncol 2007, 4(10):591-602 10.1038/ ncponc0934 17898809
2. Laviola L Natalicchio A Giorgino F The IGF-I signaling pathway Curr Pharm Des 2007, 13(7):663-9 10.2174/138161207780249146 17346182
3. Girnita L Shenoy SK Sehat B Vasilcanu R Vasilcanu D Girnita A Lefkowitz RJ Larsson O Beta-arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression J Biol Chem 2007, 282(15):11329-38 10.1074/jbc.M611526200 17303558
4. Samani AA Brodt P The receptor for the type I insulin-like growth factor and its ligands regulate multiple cellular functions that impact on metastasis Surg Oncol Clin N Am 2001, 10(2):289-312 11382588
5. Ouban A Muraca P Yeatman T Coppola D Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas Hum Pathol 2003, 34(8):803-8 10.1016/S0046-8177(03)00291-0 14506643
6. Kanter-Lewensohn L Dricu A Girnita L Wejde J Larsson O Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27Kip1 in melanocytic tumors: A potential regulatory role of IGF-1 pathway in distribution of p27Kip1 between different cyclins Growth Factors 2000, 17(3):193-202 10705577
7. Rowinsky EK Youssoufian H Tonra JR Solomon P Burtrum D Ludwig DL IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor Clin Cancer Res 2007, 13(18 Pt 2):5549s-55s 10.1158/ 1078-0432.CCR-07-1109 17875788
8. Haluska P Shaw HM Batzel GN Yin D Molina JR Molife LR Yap TA Roberts ML Sharma A Gualberto A Adjei AA de Bono JS Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors Clin Cancer Res 2007, 13(19):5834-40 10.1158/1078-0432.CCR-07-1118 17908976
9. Andrews DW Resnicoff M Flanders AE Kenyon L Curtis M Merli G Baserga R Iliakis G Aiken RD Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas J Clin Oncol 2001, 19(8):2189-200 11304771
10. Garcia-Echeverria C Pearson MA Marti A Meyer T Mestan J Zimmermann J Gao J Brueggen J Capraro HG Cozens R Evans DB Fabbro D Furet P Porta DG Liebetanz J Martiny-Baron G Ruetz S Hofmann F In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase Cancer Cell 2004, 5(3):231-9 10.1016/S1535-6108(04)00051-0 15050915
11. Gable KL Maddux BA Penaranda C Zavodovskaya M Campbell MJ Lobo M Robinson L Schow S Kerner JA Goldfine ID Youngren JF Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth Mol Cancer Ther 2006, 5(4):1079-86 10.1158/1535-7163.MCT-05-0397 16648580
12. Decensi A Bonanni B Baglietto L Guerrieri-Gonzaga A Ramazzotto F Johansson H Robertson C Marinucci I Mariette F Sandri MT Daldoss C Bianco V Buttarelli M Cazzaniga M Franchi D Cassano E Omodei U A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers Clin Cancer Res 2004, 10(13):4389-97 10.1158/1078-0432.CCR-04-0087 15240527
13. Decensi A Johansson H Miceli R Mariani L Camerini T Cavadini E Di Mauro MG Barreca A Gonzaga AG Diani S Sandri MT De Palo G Formelli F Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer Cancer Epidemiol Biomarkers Prev 2001, 10(10):1047-53 11588130
14. Decensi A Veronesi U Miceli R Johansson H Mariani L Camerini T Di Mauro MG Cavadini E De Palo G Costa A Perloff M Malone WF Formelli F Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide Clin Cancer Res 2003, 9(13):4722-9 14581342
15. Kucuk O Sarkar FH Sakr W Djuric Z Pollak MN Khachik F Li YW Banerjee M Grignon D Bertram JS Crissman JD Pontes EJ Wood DP Jr Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy Cancer Epidemiol Biomarkers Prev 2001, 10(8):861-8 11489752
16. Pollak M Lacy M Lipton A Demers L Leitzel K de Bono J Yin D Roberts L Sharma A Gualberto A A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors [abstract] Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 2007 25(18S (June 20 Supplement)):3587
17. Collett-Solberg PF Cohen P Genetics, chemistry, and function of the IGF/ IGFBP system Endocrine 2000, 12(2):121-36 10.1385/ENDO:12:2:121 10905372
18. Liu B Lee KW Anzo M Zhang B Zi X Tao Y Shiry L Pollak M Lin S Cohen P Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis Oncogene 2007, 26(12):1811-9 10.1038/sj.onc.1209977 16983336
19. Grimberg A Liu B Bannerman P El-Deiry WS Cohen P IGFBP-3 mediates p53-induced apoptosis during serum starvation Int J Oncol 2002, 21(2):327-335 12118329
20. Debacq-Chainiaux F Pascal T Boilan E Bastin C Bauwens E Toussaint O Screening of senescence-associated genes with specific DNA array reveals the role of IGFBP-3 in premature senescence of human diploid fibroblasts Free Radical Biology & Medicine 2008, 44:1817-1832 10.1016/ j.freeradbiomed.2008.02.001 18329388
21. Liu B Lee KW Li H Ma L Lin GL Chandraratna RA Cohen P Combination therapy of insulin-like growth factor binding protein-3 and retinoid X receptor ligands synergize on prostate cancer cell apoptosis in vitro and in vivo Clin Cancer Res 2005, 11(13):4851-6 10.1158/ 1078-0432.CCR-04-2160 16000583
22. Wang H Shen SS Wang H Diwan AH Zhang W Fuller GN Prieto VG Expression of insulin-like growth factor-binding protein 2 in melanocytic lesions J Cutan Pathol 2003, 30(10):599-605 10.1034/j.1600-0560.2003.00120.x 14744083
23. Xi Y Nakajima G Hamil T Fodstad O Riker A Ju J Association of insulin-like growth factor binding protein-3 expression with melanoma progression Mol Cancer Ther 2006, 5(12):3078-84 10.1158/ 1535-7163.MCT-06-0424 17172410
24. Wajapeyee N Serra RW Zhu X Mahalingam M Green MR Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7 Cell 2008, 132(3):363-74 2266096 18267069 10.1016/ j.cell.2007.12.032
25. Durai R Yang SY Sales KM Seifalian AM Goldspink G Winslet MC Insulin-like growth factor binding protein-4 gene therapy increases apoptosis by altering Bcl-2 and Bax proteins and decreases angiogenesis in colorectal cancer Int J Oncol 2007, 30(4):883-8 17332927
26. Zhu W Shiojima I Ito Y Li Z Ikeda H Yoshida M Naito AT Nishi J Ueno H Umezawa A Minamino T Nagai T Kikuchi A Asashima M Komuro I IGFBP-4 is an inhibitor of canonical Wnt signaling required for cardiogenesis Nature 2008, 454:345-350 10.1038/nature07027 18528331
27. Durai R Davies M Yang W Yang SY Seifalian A Goldspink G Winslet M Biology of insulin-like growth factor binding protein-4 and its role in cancer (review) Int J Oncol 2006, 28(6):1317-25 16685432
28. Damon SE Maddison L Ware JL Plymate SR Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation Endocrinology 1998, 139(8):3456-64 10.1210/en.139.8.3456 9681496
29. Huang SS Ling TY Tseng WF Huang YH Tang FM Leal SM Huang JS Cellular growth inhibition by IGFBP-3 and TGF-beta1 requires LRP-1 Faseb J 2003, 17(14):2068-81 10.1096/fj.03-0256com 14597676
30. Ikonen M Liu B Hashimoto Y Ma L Lee KW Niikura T Nishimoto I Cohen P Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis Proc Natl Acad Sci USA 2003, 100(22):13042-7 240741 14561895 10.1073/pnas.2135111100
31. Lee KW Ma L Yan X Liu B Zhang XK Cohen P Rapid apoptosis induction by IGFBP-3 involves an insulin-like growth factor-independent nucleomitochondrial translocation of RXRalpha/Nur77 J Biol Chem 2005, 280(17):16942-8 10.1074/jbc.M412757200 15731112
32. Aishima S Basaki Y Oda Y Kuroda Y Nishihara Y Taguchi K Taketomi A Maehara Y Hosoi F Maruyama Y Fotovati A Oie S Ono M Ueno T Sata M Yano H Kojiro M Kuwano M Tsuneyoshi M High expression of insulin-like growth factor binding protein-3 is correlated with lower portal invasion and better prognosis in human hepatocellular carcinoma Cancer Sci 2006, 97(11):1182-90 10.1111/j.1349-7006.2006.00322.x 16965600
33. Han JY Choi BG Choi JY Lee SY Ju SY The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer Lung Cancer 2006, 54(2):227-34 10.1016/j.lungcan.2006.07.014 16935391
34. Collett-Solberg PF Cohen P The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action Endocrinol Metab Clin North Am 1996, 25(3):591-614 10.1016/ S0889-8529(05)70342-X 8879988
35. Rajaram S Baylink DJ Mohan S Insulin-like growth factor-binding proteins in serum and other biological fluids: Regulation and functions Endocr Rev 1997, 18(6):801-31 10.1210/er.18.6.801 9408744